for daily banking news and anonymous message boards, check out the new site cafebanking.com


» Sponsored ads

» Sponsored ads

» Sponsored ads


Go Back   Cafepharma Message Boards > Company Boards > Valeant Pharmaceuticals
Register Members List Calendar Search Today's Posts Mark Forums Read

Reply

 
Bookmark and Share Thread Tools Rate Thread Display Modes
  #1  
Old 07-29-2013, 04:51 PM
Anonymous
 
Posts: n/a
Default Valeant Layoffs

Sorry to hear about this!!!

Valeant To Cut To 2,850 Workers After Bausch + Lomb Deal








Posted Mon, 07/29/2013 - 11:04am by Ed Silverman 1



axe-flickr1.jpg



axe-flickr1.jpg

axe


Now that Valeant Pharmaceuticals has begun digesting its $8.7 billion acquisition of Bausch & Lomb, as many as 2,850 jobs may be cut from a combined workforce of approximately 19,000 people, as the drugmaker looks to save about $800 million over the next year and a half, according to a memo to employees that was filed with the US Securities and Exchange Commission.

Specifically, Valent (VRX) will trim anywhere from 10 percent to 15 percent of its headcount, which numbers about 7,500 Valeant workers and between 11,000 and 12,000 Bausch & Lomb employees, a Valeant spokeswoman tells us. While corporate headquarters will remain in Laval, Quebec, and US headquarters and the new US eye health unit will stay in New Jersey, other facilities will be moved or closed.

Meanwhile, the new management team looks like this: Laizer Kornwaiser is exec vp and company group chair for Canada, neurology and oral health; Pavel Mirovsky is exec vp, president gm for Europe; Howard Schiller is exec vp and cfo; Rob Chai-Onn is exec vp and general counsel; Brian Stolz is exec vp and chief of HR, and Ryan Welcon is exec vvp and group chair for the Medicis unit.

Who’s leaving? Sue Hall, the global head of R&D at Valeant, along with most of the executive team at Bausch & Lomb: Bob Bailey, John Barr, Bob Bertolini, Alan Farnsworth, Mariano Garcia-Valino, Mike Gowen, Brian Harris, Rick Heinick, Sheila Hopkins, Susan Roberts, Rod Unsworth and Charl van Zyl. A prominent exception is Dan Weschler, who is now exec vp and group chair for Bausch & Lomb.

STORY ENDS HERE

axe pic thx to brittgow on flickr
.
Log in or register to post comments
.

1 Comment
original indust... Jul 29, 2013 - 11:54am




The nice part about massive layoffs is that the acquiring company can structure the charge against earnings in a way that will minimize it's hit to the bottom line.

. ......





..

Latest Stories







Pfizer Creates Three Separate Businesses, But Spinoffs Are Not Imminent
.



Pharmacists Group Lobbies Against Senate Compounding Bill
.



Another Pharma Deal Spurred, In Part, By A Lower Irish Tax Rate
.
Reply With Quote
  #2  
Old 08-03-2013, 01:30 PM
Anonymous
 
Posts: n/a
Default Re: Valeant Layoffs

Quote:
Originally Posted by Anonymous View Post
Sorry to hear about this!!!

Valeant To Cut To 2,850 Workers After Bausch + Lomb Deal








Posted Mon, 07/29/2013 - 11:04am by Ed Silverman 1



axe-flickr1.jpg



axe-flickr1.jpg

axe


Now that Valeant Pharmaceuticals has begun digesting its $8.7 billion acquisition of Bausch & Lomb, as many as 2,850 jobs may be cut from a combined workforce of approximately 19,000 people, as the drugmaker looks to save about $800 million over the next year and a half, according to a memo to employees that was filed with the US Securities and Exchange Commission.

Specifically, Valent (VRX) will trim anywhere from 10 percent to 15 percent of its headcount, which numbers about 7,500 Valeant workers and between 11,000 and 12,000 Bausch & Lomb employees, a Valeant spokeswoman tells us. While corporate headquarters will remain in Laval, Quebec, and US headquarters and the new US eye health unit will stay in New Jersey, other facilities will be moved or closed.

Meanwhile, the new management team looks like this: Laizer Kornwaiser is exec vp and company group chair for Canada, neurology and oral health; Pavel Mirovsky is exec vp, president gm for Europe; Howard Schiller is exec vp and cfo; Rob Chai-Onn is exec vp and general counsel; Brian Stolz is exec vp and chief of HR, and Ryan Welcon is exec vvp and group chair for the Medicis unit.

Who’s leaving? Sue Hall, the global head of R&D at Valeant, along with most of the executive team at Bausch & Lomb: Bob Bailey, John Barr, Bob Bertolini, Alan Farnsworth, Mariano Garcia-Valino, Mike Gowen, Brian Harris, Rick Heinick, Sheila Hopkins, Susan Roberts, Rod Unsworth and Charl van Zyl. A prominent exception is Dan Weschler, who is now exec vp and group chair for Bausch & Lomb.

STORY ENDS HERE

axe pic thx to brittgow on flickr
.
Log in or register to post comments
.

1 Comment
original indust... Jul 29, 2013 - 11:54am




The nice part about massive layoffs is that the acquiring company can structure the charge against earnings in a way that will minimize it's hit to the bottom line.

. ......





..

Latest Stories







Pfizer Creates Three Separate Businesses, But Spinoffs Are Not Imminent
.



Pharmacists Group Lobbies Against Senate Compounding Bill
.



Another Pharma Deal Spurred, In Part, By A Lower Irish Tax Rate
.


This number appears to be all over the place. If its a dollar amount, it's not the amount of people, but who.
Reply With Quote
  #3  
Old 08-05-2013, 01:43 AM
Anonymous
 
Posts: n/a
Default Re: Valeant Layoffs

Do Tage and Peter know about eyeballs?
Reply With Quote
  #4  
Old 08-06-2013, 03:14 PM
Anonymous
 
Posts: n/a
Default Re: Valeant Layoffs

Quote:
Originally Posted by Anonymous View Post
Do Tage and Peter know about eyeballs?
They know about balls.
Reply With Quote
  #5  
Old 08-06-2013, 06:31 PM
Anonymous
 
Posts: n/a
Default Re: Valeant Layoffs

D-Day.
Reply With Quote
Reply




Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may post new threads
You may post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is Off
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 05:38 AM.


Powered by vBulletin® Version 3.6.11
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.